Article Impact Level: HIGH Data Quality: STRONG Summary of The University of Hong Kong https://doi.org/10.1007/s00408-025-00792-9 Dr. Wang Chun Kwok et al.
Points
- Measuring changes in blood eosinophil counts between stable periods and exacerbations can predict future COPD exacerbation risk.
- A difference in blood eosinophil count of ≥105 cells/µL significantly shortens the time to the next acute COPD exacerbation.
- Patients with this higher eosinophil difference experienced a greater annual number of subsequent acute exacerbations.
- The presence of Pseudomonas aeruginosa in sputum colonization also significantly elevates the risk of future COPD exacerbations.
- These findings emphasize the importance of personalized treatment strategies, integrating dynamic biomarkers and sputum analysis for COPD management.
Summary
A prospective study investigated the role of dynamic changes in blood eosinophil count (BEC) in predicting subsequent acute exacerbations of COPD (AECOPD). Among 348 Chinese patients with COPD, 158 who experienced an index moderate-to-severe AECOPD were analyzed. The absolute eosinophil difference (BEC at index exacerbation [Ei] – baseline BEC [E0]) was used as a key metric. Utilizing a cut-off of 105 cells/µL for this absolute eosinophil difference, determined by receiver operating characteristic (ROC) analysis, patients with a difference ≥105 cells/µL demonstrated a significantly shorter time to subsequent AECOPD.
These patients with a higher absolute eosinophil difference showed an adjusted hazard ratio (aHR) of 1.68 (95% CI = 1.02–2.74; p = 0.040) for a shorter time to next AECOPD. Furthermore, this subgroup also experienced a higher annual number of subsequent AECOPD (2.49 ± 2.84/year vs 1.58 ± 2.44/year, p = 0.023). Similar predictive findings were observed in the subgroup of patients with a stable-state baseline BEC <300 cells/µL, indicating the robustness of this dynamic eosinophil metric even in patients typically not considered to have high baseline eosinophilia.
Beyond blood parameters, sputum analysis revealed that approximately 10% of COPD patients harbored Pseudomonas aeruginosa colonization in their airways, which was independently linked to an elevated risk of future exacerbations. These findings, alongside the revised Global Initiative for Chronic Obstructive Lung Disease Report 2026 criteria for high-risk patients (at least one moderate exacerbation in the previous year), underscore the importance of multifactorial risk assessment. This includes dynamic BEC monitoring and sputum microbiological analysis to facilitate personalized treatment strategies for preventing and managing COPD exacerbations effectively.
Link to the article: https://link.springer.com/article/10.1007/s00408-025-00792-9
References
Kwok, W. C., Tam, T. C. C., Chau, C. H., Lam, F. M., & Ho, J. C. M. (2025). Differences in blood eosinophil level during stable disease and during exacerbation of copd and exacerbation risks. Lung, 203(1), 37. https://doi.org/10.1007/s00408-025-00792-9
